Compare Incyte Corporation (INCY) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs T Rowe Price Group Inc — how do they compare? Incyte Corporation trades at $113.7 (market cap $22.85B), while T Rowe Price Group Inc trades at $104.98 (market cap $22.23B). The key difference: Incyte Corporation and T Rowe Price Group Inc are close in size by market cap, and T Rowe Price Group Inc pays a 4.99% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and T Rowe Price Group Inc for 115 Days on average.
| INCY | TROW | |
|---|---|---|
Market Cap | $22.85B | $22.23B |
Volume | 1,927,029 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $129.93 | $121.68 |
52-Week Low | $83.80 | $86.19 |
Typical Hold Time | 33 Days | 115 Days |
Enterprise Value | $18.35B | $19.43B |
Dividend Yield | — | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
T. Rowe Price (TROW) trades at $105.47, up 1.35% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with a P/E of 10.46, net income margin of 29.26%, and consistent dividend growth spanning 40 years. Recent earnings beat expectations in Q1 and Q2 2026, while AUM reached $1.90 trillion in August 2026 despite net outflows.
The stock presents value characteristics with attractive valuation multiples and dividend yield near 5%, though technical weakness and analyst caution (63% hold rating) suggest near-term consolidation. Key catalysts include Q3 earnings due soon and the company's expansion into ETF offerings through F/m Investments acquisition, while risks include market-sensitive revenue and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
